Oramed Pharmaceuticals Company Profile (NASDAQ:ORMP)

About Oramed Pharmaceuticals

Oramed Pharmaceuticals logoOramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed's flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed's delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company's products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ORMP
  • CUSIP:
Key Metrics:
  • Previous Close: $7.84
  • 50 Day Moving Average: $7.5789
  • 200 Day Moving Average: $7.9744
  • 52-Week Range: $5.46 - $10.74
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.88
  • P/E Growth: 0.0000
  • Market Cap: $103.03M
  • Outstanding Shares: 13,136,000
  • Beta: 0.44
Profitability:
  • Return on Equity: -28.25%
  • Return on Assets: -25.11%
Debt:
  • Current Ratio: 18.90%
  • Quick Ratio: 18.90%
Additional Links:
Companies Related to Oramed Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Oramed Pharmaceuticals (NASDAQ:ORMP) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $22.00 (180.49% upside)

Analysts' Ratings History for Oramed Pharmaceuticals (NASDAQ:ORMP)
Show:
DateFirmActionRatingPrice TargetDetails
8/21/2016Rodman & RenshawReiterated RatingBuy$25.00View Rating Details
5/26/2016FBR & CoBoost Price TargetOutperform$15.00 -> $20.00View Rating Details
5/18/2016AegisReiterated RatingBuy$18.00View Rating Details
12/1/2015HC WainwrightBoost Price TargetBuy$24.00 -> $25.00View Rating Details
7/8/2015MLV & Co.Reiterated RatingBuyView Rating Details
(Data available from 9/24/2014 forward)

Earnings

Earnings History for Oramed Pharmaceuticals (NASDAQ:ORMP)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Oramed Pharmaceuticals (NASDAQ:ORMP)
Current Year EPS Consensus Estimate: $-0.62 EPS
Next Year EPS Consensus Estimate: $-0.66 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.20)($0.20)($0.20)
Q2 20161($0.20)($0.20)($0.20)
Q3 20161($0.22)($0.22)($0.22)
Q4 20161($0.23)($0.23)($0.23)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Oramed Pharmaceuticals (NASDAQ:ORMP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Oramed Pharmaceuticals (NASDAQ:ORMP)
Insider Ownership Percentage: 25.90%
Institutional Ownership Percentage: 1.69%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2016Nadav KidronCEOBuy1,000$6.95$6,950.00View SEC Filing  
12/30/2015Miriam KidronCTOSell50,000$8.90$445,000.00View SEC Filing  
12/9/2015Michael BerelowitzDirectorSell700$9.44$6,608.00View SEC Filing  
12/8/2015Michael BerelowitzDirectorSell1,300$8.70$11,310.00View SEC Filing  
3/19/2015Nadav KidronCEOBuy2,600$3.88$10,088.00View SEC Filing  
9/11/2014Miriam KidronCTOSell31,699$8.41$266,588.59View SEC Filing  
9/10/2014Miriam KidronCTOSell23,000$8.40$193,200.00View SEC Filing  
9/4/2014Miriam KidronCTOSell8,301$9.41$78,112.41View SEC Filing  
6/6/2014Regals Capital Management LpMajor ShareholderBuy2,252$4.44$9,998.88View SEC Filing  
3/31/2014Michael BerelowitzDirectorSell9,434$10.50$99,057.00View SEC Filing  
3/25/2014Regals Capital Management Lpmajor shareholderBuy75,000$10.62$796,500.00View SEC Filing  
2/6/2014Regals Capital Management Lpmajor shareholderBuy51,292$15.61$800,668.12View SEC Filing  
7/10/2013Regals Capital Management LpMajor ShareholderBuy6,630$7.40$49,062.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Oramed Pharmaceuticals (NASDAQ:ORMP)
DateHeadline
seekingalpha.com logoDiabetes Patients Need Earlier Administration Insulin: Novo Nordisk And Oramed Take The Lead (NASDAQ:ORMP)
seekingalpha.com - September 19 at 6:37 PM
finance.yahoo.com logoOramed to Present at the Aegis Capital Growth Conference (NASDAQ:ORMP)
finance.yahoo.com - September 19 at 11:07 AM
News IconAnalyst Consensus Estimates & Projections are in For Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Frisco Fastball (NASDAQ:ORMP)
friscofastball.com - September 13 at 11:30 AM
finance.yahoo.com logoOramed to Present at the Rodman & Renshaw Global Investment Conference (NASDAQ:ORMP)
finance.yahoo.com - September 7 at 10:09 AM
biz.yahoo.com logoORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a (NASDAQ:ORMP)
biz.yahoo.com - September 1 at 9:48 AM
investornewswire.com logoWill Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Hit $30 Price Target? - Investor Newswire (NASDAQ:ORMP)
www.investornewswire.com - August 21 at 5:54 PM
investornewswire.com logoWill Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Hit $30 Price Target? - Investor Newswire (NASDAQ:ORMP)
www.investornewswire.com - August 21 at 5:54 PM
finance.yahoo.com logoOramed (ORMP) Reports Additional Positive Data from Phase IIb ORMD-0801 Study (NASDAQ:ORMP)
finance.yahoo.com - August 11 at 7:08 PM
streetinsider.com logoOramed Pharma (ORMP) Receives Additional Milestone Related to ORMD-0801 Phase 2b - StreetInsider.com (NASDAQ:ORMP)
www.streetinsider.com - August 3 at 9:56 AM
finance.yahoo.com logoOramed Receives Additional $4 Million Milestone Payment From HTIT (NASDAQ:ORMP)
finance.yahoo.com - August 2 at 11:37 AM
marketexclusive.com logoOramed Gets Buy Rating From FBR & Co. Target: $20 (NASDAQ:ORMP)
marketexclusive.com - July 29 at 6:49 PM
seekingalpha.com logoOramed: Progress On Oral Insulin Pill (NASDAQ:ORMP)
seekingalpha.com - July 28 at 6:57 PM
4-traders.com logoOramed Pharmaceuticals : Appoints Dr. Roy Eldor as Chief Medical Director (NASDAQ:ORMP)
www.4-traders.com - July 28 at 6:57 PM
streetinsider.com logoOramed Pharma (ORMP) Announces Significant Additional Data for ORMD-0801 in T2D (NASDAQ:ORMP)
www.streetinsider.com - July 28 at 6:57 PM
biz.yahoo.com logoORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events (NASDAQ:ORMP)
biz.yahoo.com - July 28 at 4:33 PM
streetinsider.com logoOramed Pharma (ORMP) Announces Significant Additional Data for ORMD-0801 in T2D - StreetInsider.com (NASDAQ:ORMP)
www.streetinsider.com - July 28 at 9:51 AM
finance.yahoo.com logoOramed Reports Additional Phase IIb Oral Insulin Study Data Demonstrating Significant Lowering of Glucose Levels vs Placebo (NASDAQ:ORMP)
finance.yahoo.com - July 28 at 8:15 AM
seekingalpha.com logoOramed: Progress On Oral Insulin Pill - Seeking Alpha (NASDAQ:ORMP)
seekingalpha.com - July 27 at 7:00 PM
investornewswire.com logoIs $30 Price Target Attainable For Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)? - Investor Newswire (NASDAQ:ORMP)
www.investornewswire.com - July 26 at 9:56 AM
finance.yahoo.com logo9:44 am Oramed Pharmaceuticals appointed Dr. Roy Eldor MD PhD to the newly created position of Chief Medical Director (NASDAQ:ORMP)
finance.yahoo.com - July 26 at 9:44 AM
finance.yahoo.com logoOramed Appoints Dr. Roy Eldor as Chief Medical Director (NASDAQ:ORMP)
finance.yahoo.com - July 26 at 9:00 AM
investornewswire.com logoStrong Sell Calls For Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) At 0 - Investor Newswire (NASDAQ:ORMP)
www.investornewswire.com - July 18 at 12:08 PM
News IconOramed Pharmaceuticals Incorporated (NASDAQ:ORMP) Short Interest Decreased By 9.98% - Press Telegraph (NASDAQ:ORMP)
presstelegraph.com - July 17 at 6:06 PM
ftsenews.co.uk logoNew Broker Ratings For Oramed Pharmaceuticals Inc. (ORMP) - FTSE News (NASDAQ:ORMP)
www.ftsenews.co.uk - July 16 at 9:57 AM
News IconOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:ORMP)
www.engelwooddaily.com - July 15 at 11:42 AM
News IconOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Wall Street Analyst Recommendation Outlook - Telanagana Press (NASDAQ:ORMP)
telanaganapress.com - July 13 at 7:03 PM
investornewswire.com logoIs $30 Within Reach For Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)? - Investor Newswire (NASDAQ:ORMP)
www.investornewswire.com - July 12 at 6:55 PM
News IconHow Many Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP)'s Analysts Are Bullish? - Press Telegraph (NASDAQ:ORMP)
presstelegraph.com - July 12 at 6:55 PM
finance.yahoo.com logoORAMED PHARMACEUTICALS INC. Financials (NASDAQ:ORMP)
finance.yahoo.com - July 12 at 1:04 PM
News IconCan Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Improve on the Earnings Front? - Engelwood Daily (NASDAQ:ORMP)
www.engelwooddaily.com - July 8 at 9:36 AM
News IconCompany Stock Focus for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP): Which Way Will Shares Head? - Press Telegraph (NASDAQ:ORMP)
presstelegraph.com - July 8 at 9:36 AM
fiscalstandard.com logoBroker Outlook For Oramed Pharmaceuticals Inc. (ORMP) - Fiscal Standard (NASDAQ:ORMP)
www.fiscalstandard.com - July 8 at 9:36 AM
News IconOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Stock Update: Check on Ratings and Target Price - Telanagana Press (NASDAQ:ORMP)
telanaganapress.com - July 6 at 6:53 PM
ftsenews.co.uk logoOramed Pharmaceuticals Inc. (ORMP) Updated Price Targets - FTSE News (NASDAQ:ORMP)
www.ftsenews.co.uk - July 6 at 6:53 PM
sg.finance.yahoo.com logoOramed reports 3Q loss (NASDAQ:ORMP)
sg.finance.yahoo.com - July 6 at 4:58 PM
fiscalstandard.com logoBroker Outlook For The Week Ahead Oramed Pharmaceuticals Inc. (ORMP) - Fiscal Standard (NASDAQ:ORMP)
www.fiscalstandard.com - July 4 at 5:57 PM
News IconOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Earnings Glance and Target Price Review - Engelwood Daily (NASDAQ:ORMP)
www.engelwooddaily.com - July 1 at 6:41 PM
fiscalstandard.com logoOramed Pharmaceuticals Inc. (ORMP) Current Analyst Ratings - Fiscal Standard (NASDAQ:ORMP)
www.fiscalstandard.com - July 1 at 6:41 PM
News IconOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Company Rating and Target Watch - Telanagana Press (NASDAQ:ORMP)
telanaganapress.com - June 29 at 9:32 AM
investornewswire.com logoStrong Sell Calls Recommendations For Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) At 0 - Investor Newswire (NASDAQ:ORMP)
www.investornewswire.com - June 27 at 10:50 AM
News IconCovering the Bases on Oramed Pharmaceuticals Inc. (NASDAQ:ORMP): Where is the Stock Going? - Press Telegraph (NASDAQ:ORMP)
presstelegraph.com - June 26 at 11:11 AM
streetinsider.com logoOramed Pharma (ORMP) Receives Milestone Payment Related to HTIT License, Investment Agreement (NASDAQ:ORMP)
www.streetinsider.com - June 22 at 6:36 PM
insidermonkey.com logoThe Top Four Diabetes Best Sellers and One Oral Insulin Pill That May Threaten Them All (NASDAQ:ORMP)
www.insidermonkey.com - June 22 at 12:20 PM
finance.yahoo.com logoOramed Announces $6.5 Million Milestone Payment from HTIT (NASDAQ:ORMP)
finance.yahoo.com - June 21 at 6:14 PM
streetinsider.com logoOramed Pharma (ORMP) Receives Milestone Payment Related to HTIT License, Investment Agreement - StreetInsider.com (NASDAQ:ORMP)
www.streetinsider.com - June 21 at 11:05 AM
investornewswire.com logoStrong Buy Calls Count For Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) At 3 - Investor Newswire (NASDAQ:ORMP)
www.investornewswire.com - June 20 at 8:17 AM
fiscalstandard.com logoOramed Pharmaceuticals Inc. (ORMP) Analyst Price Targets For The Coming Week - Fiscal Standard (NASDAQ:ORMP)
www.fiscalstandard.com - June 20 at 8:17 AM
biz.yahoo.com logoORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:ORMP)
biz.yahoo.com - June 16 at 10:19 AM
247wallst.com logo3 Biotechs That Just Announced Successful Phase 2 Trials (NASDAQ:ORMP)
247wallst.com - June 11 at 9:20 AM
finance.yahoo.com logoOramed to Present at the American Diabetes Association 76th Scientific Sessions (NASDAQ:ORMP)
finance.yahoo.com - June 9 at 8:15 AM

Social

Oramed Pharmaceuticals (NASDAQ:ORMP) Chart for Saturday, September, 24, 2016


Last Updated on 9/24/2016 by MarketBeat.com Staff